Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed) | PA 18 821

Opportunity Information: Apply for PA 18 821

Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed) is an NIH/National Cancer Institute (NCI) administrative supplement opportunity designed to add targeted, collaborative cancer cachexia work onto an existing NCI-funded research grant. The central aim is to support multidisciplinary basic and translational research that tackles an important, well-defined question in cancer cachexia, while also growing the pool of investigators who know how to design cachexia studies, choose and use appropriate model systems, and interpret cachexia-related data correctly. In practice, the program is meant to help cancer-focused teams partner with cachexia experts so that cachexia biology is studied with the same rigor and domain-specific experience that exists in more established fields.

A key requirement is that the supplement application must be built around a true collaboration between two types of researchers: cancer researchers and investigators with documented expertise in cachexia research. This is not just a preference; it is a structural expectation of the supplement, reflecting the idea that cachexia spans tumor biology, metabolism, immunology, muscle and adipose biology, and multi-organ physiology, and therefore benefits from integrated expertise. Another important eligibility condition is that the parent grant receiving the supplement must have an NCI primary assignment, meaning the underlying active award is already within NCI's portfolio.

The long-term goal of the initiative is broader than adding a single set of experiments. NCI is signaling interest in a more focused and sustained examination of the biology of cancer cachexia and, especially, how cachexia affects organs and systems beyond the tumor itself. That emphasis points toward mechanistic and systems-level questions, including the cross-talk between tumors and peripheral tissues, and the downstream functional consequences for the patient. The notice also emphasizes that this is not a clinical trial mechanism, so applicants should plan work that fits within basic or translational scopes without proposing a clinical trial.

Administratively, this is a discretionary grant opportunity listed under Funding Opportunity Number PA 18 821, within the Health funding activity category, and associated with CFDA number 93.310. Because it is an administrative supplement, it is intended to provide additional support linked to an existing award rather than fund an entirely new standalone project. The original closing date shown is 2018-07-30, and the record does not specify an award ceiling or expected number of awards in the source text provided.

Eligibility is broad and includes many common applicant types across government, academia, nonprofit, and industry, as long as the supplement is tied to an eligible parent grant. Eligible applicants listed include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses) and small businesses; and other entities. The opportunity also explicitly highlights additional eligible organization categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities.

Finally, the notice strongly encourages prospective applicants to contact the NCI scientific staff associated with the opportunity before submitting a request. That kind of outreach is typically important for administrative supplements because NCI program staff can advise whether the proposed collaborative scope fits the goals of the supplement, aligns with the parent grant, and is likely to be viewed as responsive to NCI's cachexia research priorities.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310.
• This funding opportunity was created on 2018-06-07.
• Applicants must submit their applications by 2018-07-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 18 821

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: